International AIDS Vaccine Initiative
A003 Protocol - A Phase 1, randomized, blinded, dose-escalation study of rAAV1-PG9DP recombinant AAV vector coding for PG9 antibody in healthy male adults
Frances H. Priddy
Table for Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa
MOESM2 of Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes
Correlation between total and antigen-specific IgG responses and development of broadly neutralizing antibody responses.
Specificities mediating neutralization breadth and potency in the top 42 Protocol C neutralizers.
Evolution of broadly neutralizing antibody responses in plasma from Protocol C participants.
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
Correlation between clinical parameters and development of broadly neutralizing antibody responses.
HIV incidence stratified by duration of time in study follow up, and (where data were available) by study year.
Enrollment and HIV incidence among at-risk volunteers enrolled for HIV prevention preparatory studies stratified by CRC and, where appropriate, sex.